To clarify the immunosuppressive action of T-96 in vitiligo, tofacitinib (Tofa) was used as a positive control, in that Tofa could induce successful repigmentation in vitiligo patients [34] and suppress CD8+ T cells function in our previous study [35]. The gene discussed is CD8A; the disease is vitiligo.